Three 2026 Breakthrough Prize winners reflect on developing Luxturna, a gene therapy that treats blindness caused by rare ...
Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, and ...
The FDA has granted accelerated approval to Regeneron Pharmaceuticals’ Otarmeni™ (lunsotogene parvec-cwha) as the first gene ...
Kelly Anne is a deputy editor at Forbes Advisor overseeing the development of various initiatives, including newsletters, ...
Hearing loss is a condition that affect numerous people around the world, but it can take many forms and have many causes. In ...
The FDA has approved Otarmeni, the first-ever gene therapy for genetic hearing loss caused by the OTOF gene, for both ...
A breakthrough FDA-approved treatment is changing how genetic deafness is treated.
Danish dermatology specialist Leo Pharma is paying $50 million for U.S. gene writing biotech Replay and its preclinical gene ...
The Translational Genomics Research Institute (TGen), part of City of Hope, today announced the launch of JAYseqTM, a ...
We performed a post hoc analysis of a single-center phase II trial (ClinicalTrials.gov identifier: NCT03503643) in which patients with unilateral grade group (GG) 2-4 PCa (n = 108) underwent hemigland ...
New technology enables the insertion of a large segment of DNA into a genome, potentially expanding gene therapy treatment ...